MX383271B - Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno. - Google Patents

Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno.

Info

Publication number
MX383271B
MX383271B MX2017003625A MX2017003625A MX383271B MX 383271 B MX383271 B MX 383271B MX 2017003625 A MX2017003625 A MX 2017003625A MX 2017003625 A MX2017003625 A MX 2017003625A MX 383271 B MX383271 B MX 383271B
Authority
MX
Mexico
Prior art keywords
cells
specific
enriching
reagents
identifying
Prior art date
Application number
MX2017003625A
Other languages
English (en)
Other versions
MX2017003625A (es
Inventor
Joan Glick Bieler
Jonathan Schneck
Karlo Perica
Mathias Oelke
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2017003625A publication Critical patent/MX2017003625A/es
Publication of MX383271B publication Critical patent/MX383271B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/02—Magnetic separation acting directly on the substance being separated
    • B03C1/28—Magnetic plugs and dipsticks
    • B03C1/288—Magnetic plugs and dipsticks disposed at the outer circumference of a recipient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/18—Magnetic separation whereby the particles are suspended in a liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/20—Magnetic separation of bulk or dry particles in mixtures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/26—Details of magnetic or electrostatic separation for use in medical or biological applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a las células T específicas de antígeno, que incluyen las células T sin tratamiento, e incluyen células precursoras inusuales se enriquecen y expanden en cultivo. El enriquecimiento y la expansión proporcionan una plataforma para una inmunoterapia más eficaz por transferencia adoptiva, así como plataformas para personalizar la inmunoterapia mediante la determinación de la reactividad de células T con un banco de antígenos peptídicos candidatos.
MX2017003625A 2014-09-17 2015-09-17 Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno. MX383271B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051660P 2014-09-17 2014-09-17
US201562170541P 2015-06-03 2015-06-03
PCT/US2015/050593 WO2016044530A1 (en) 2014-09-17 2015-09-17 Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells

Publications (2)

Publication Number Publication Date
MX2017003625A MX2017003625A (es) 2017-10-11
MX383271B true MX383271B (es) 2025-03-13

Family

ID=55533827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003625A MX383271B (es) 2014-09-17 2015-09-17 Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno.

Country Status (11)

Country Link
US (3) US10987412B2 (es)
EP (1) EP3194577A4 (es)
JP (2) JP7029294B2 (es)
KR (3) KR20170078619A (es)
CN (2) CN113791208B (es)
AU (2) AU2015317712B2 (es)
CA (2) CA3017170C (es)
IL (1) IL251261B (es)
MX (1) MX383271B (es)
SG (1) SG11201702191YA (es)
WO (1) WO2016044530A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
KR102164405B1 (ko) * 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US10987412B2 (en) * 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
AU2015371265B2 (en) 2014-12-24 2021-06-03 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
CN114277081A (zh) 2015-02-22 2022-04-05 里兰斯坦福初级大学理事会 微筛选装置、方法和产品
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
JP2019511903A (ja) 2016-02-19 2019-05-09 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ 免疫原性調節の方法
AU2017271128A1 (en) * 2016-05-25 2019-01-03 The Council Of The Queensland Institute Of Medical Research Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
KR102456488B1 (ko) 2016-07-21 2022-10-19 버클리 라잇츠, 인크. 미세유체 디바이스에서의 t 림프구들의 분류
CN115254210A (zh) 2016-11-14 2022-11-01 浩康生物系统公司 用于分选目标颗粒的方法和装置
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
KR102148866B1 (ko) * 2017-08-10 2020-10-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
BR112020005552A2 (pt) 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
WO2019086711A1 (en) * 2017-11-06 2019-05-09 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
KR20210095157A (ko) * 2018-11-08 2021-07-30 넥스이뮨, 인크. 개선된 표현형 속성을 갖는 t 세포 조성물
CA3132041A1 (en) * 2019-03-06 2020-09-10 Gritstone Bio, Inc. Identification of neoantigens with mhc class ii model
MX2021012004A (es) * 2019-03-30 2021-11-04 Biontech Us Inc Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas.
WO2020237134A1 (en) * 2019-05-22 2020-11-26 Baylor Research Institute One step artificial antigen presenting cell-based vaccines
US20220381770A1 (en) * 2019-10-29 2022-12-01 Universitaet Heidelberg Artificial antigen presenting molecules and their uses
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021262846A1 (en) * 2020-06-26 2021-12-30 The Johns Hopkins University Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
KR20230065251A (ko) 2020-08-07 2023-05-11 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 t 세포를 풍부화시키기 위한 방법
CN116948964A (zh) 2020-11-19 2023-10-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
WO2022135525A1 (zh) * 2020-12-24 2022-06-30 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
US20240085417A1 (en) * 2021-01-20 2024-03-14 Memorial Sloan Kettering Cancer Center Peripheral blood phenotype linked to outcomes after immunotherapy treatment
KR102769935B1 (ko) * 2021-03-30 2025-02-19 한국과학기술원 펩타이드-mhc에 대한 t 세포 활성의 예측 방법 및 분석장치
CN116731964A (zh) * 2022-05-26 2023-09-12 苏州尔生生物医药有限公司 用于预防或治疗癌症的特异性t细胞及其制备方法
WO2025085216A1 (en) * 2023-10-19 2025-04-24 The Brigham And Women's Hospital, Inc. T-switch: a specificity-based engineering platform for developing safe and effective t cell therapeutics
GB202318977D0 (en) * 2023-12-12 2024-01-24 Swarm Oncology Ltd Method

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0937251B1 (en) * 1996-09-06 2006-11-29 Ortho-McNeil Pharmaceutical, Inc. Purification of antigen-specific t cells
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
WO2002065992A2 (en) * 2001-02-20 2002-08-29 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
CN1953767B (zh) * 2004-01-08 2011-03-16 加利福尼亚大学董事会 调节t细胞抑制自身免疫
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
WO2009094273A2 (en) * 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
US20110256147A1 (en) * 2008-12-01 2011-10-20 The Johns Hopkins University Diagnostic and treatment methods for cancer based on immune inhibitors
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
KR102095670B1 (ko) * 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP2404618A1 (en) * 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
WO2013086500A1 (en) * 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
ES2820729T3 (es) 2013-02-15 2021-04-22 Univ Johns Hopkins Redirectores de células T específicas de antígenos
KR102164405B1 (ko) * 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US11807675B2 (en) * 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
IL313845A (en) * 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015188839A2 (en) * 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US10987412B2 (en) * 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells

Also Published As

Publication number Publication date
AU2015317712B2 (en) 2019-01-17
EP3194577A4 (en) 2018-04-04
CA3017170C (en) 2021-03-23
US10987412B2 (en) 2021-04-27
EP3194577A1 (en) 2017-07-26
AU2019202508A1 (en) 2019-05-02
US20210252121A1 (en) 2021-08-19
KR20170078619A (ko) 2017-07-07
CN113791208A (zh) 2021-12-14
AU2019202508B2 (en) 2021-07-01
CA2961749C (en) 2021-01-12
IL251261B (en) 2020-08-31
JP2017529080A (ja) 2017-10-05
CA3017170A1 (en) 2016-03-24
AU2015317712A1 (en) 2017-04-27
US20180043003A1 (en) 2018-02-15
CN113791208B (zh) 2024-09-24
MX2017003625A (es) 2017-10-11
CA2961749A1 (en) 2016-03-24
WO2016044530A1 (en) 2016-03-24
US20170246277A1 (en) 2017-08-31
JP7029294B2 (ja) 2022-03-03
CN107002038B (zh) 2021-10-15
KR20210032011A (ko) 2021-03-23
JP7204719B2 (ja) 2023-01-16
SG11201702191YA (en) 2017-04-27
CN107002038A (zh) 2017-08-01
IL251261A0 (en) 2017-05-29
JP2021006051A (ja) 2021-01-21
KR20200055808A (ko) 2020-05-21
US10098939B2 (en) 2018-10-16
KR102229421B1 (ko) 2021-03-19

Similar Documents

Publication Publication Date Title
MX2017003625A (es) Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno.
PE20171136A1 (es) Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
GB2516196A8 (en) Methods, compositions, kits, and systems for selective enrichment of target cells
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
BR112017018885A2 (pt) método de cultura celular para células-tronco mesenquimais
MX370265B (es) Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
NZ726989A (en) Improved t cell compositions
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
MX2020009670A (es) Metodos de cultivo por perfusion y usos de los mismos.
MX389827B (es) Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
AU2015209540A8 (en) Cellular platform for rapid and comprehensive T-cell immunomonitoring
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
CY1122993T1 (el) Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
NZ742068A (en) Transposon system, kit comprising the same, and uses thereof
MX2017004288A (es) Medio de induccion y metodos para el cultivo de y terapias con celulas madre.